Post-marketing safety of elacestrant in breast cancer: a pharmacovigilance investigation using the FDA adverse event reporting system.

April
SunMonTueWedThuFriSat
303112345678910111213141516171819202122232425262728293012345678910
April
SunMonTueWedThuFriSat
303112345678910111213141516171819202122232425262728293012345678910
Copyright © Ark Medical Solutions Inc. All Rights Reserved.